Literature DB >> 12086355

Bone mineral density and metabolism in familial dysautonomia.

C Maayan1, E Bar-On, A J Foldes, B Gesundheit, R Dresner Pollak.   

Abstract

Familial dysautonomia (FD) patients suffer from multiple fractures and have reduced bone pain, which defers the diagnosis. The pathogenesis of bone fragility in FD is unknown. This study aimed to characterize bone mineral metabolism and density in FD. Seventy-nine FD patients aged 8 months to 48 years (mean age 13.9 +/- 10.4 years, median 12.3) were studied. Clinical data included weight, height, bone age, weekly physical activity and history of fractures. Bone mineral density (BMD) of the lumbar spine (n = 43), femoral neck (n = 26), total hip (n = 22) and whole body (n = 15) were determined by dual-energy X-ray absorptiometry. Serum 25-hydroxyvitamin D3, osteocalcin, bone alkaline phosphatase (B-ALP), parathyroid hormone and urinary N-telopeptide cross-linked type 1 collagen (NTx) were determined in 68 patients and age- and sex-matched controls. Forty-two of 79 patients (53%) sustained 75 fractures. Twenty-four of 43 patients had a spine Z-score < -2.0, and 13 of 26 had a femoral neck Z-score < -2.0. Mean femoral neck BMD Z-score was lower in patients with fractures compared with those without (-2.5 +/- 0.9 vs -1.5 +/- 1.0, p = 0.01). Mean body mass index (BMI) was 16 kg/m2 in prepubertal patients and 18.4 kg/m2 in postpubertal patients. Bone age was significantly lower than chronological age (75.5 vs 99.3 months in prepubertal patients, p < 0.001; 151 vs 174 in postpubertal patients, p < 0.05). NTx and osteocalcin levels were higher in FD patients compared with controls (400 +/- 338 vs 303 +/- 308, BCE/mM creatinine p < 0.02; 90 +/- 59.5 vs 61.8 +/- 36.9 ng/ml, p < 0.001, respectively). B-ALP was lower in FD patients compared with controls (44.66 +/- 21.8 vs 55.36 +/- 36.6 ng/ml, p < 0.04). Mean spine Z-score was significantly lower in physically inactive compared with active patients (-3.00 +/- 1.70 vs -1.77 +/- 1.3, respectively, p = 0.05). We conclude that fractures in FD patients are associated with reduced BMD. FD patients have increased NTx and osteocalcin. Contributing factors include reduced BMI, failure to thrive and reduced physical activity. Preventive therapy and early diagnosis are essential.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086355     DOI: 10.1007/s001980200050

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  14 in total

Review 1.  Impact of the Autonomic Nervous System on the Skeleton.

Authors:  Florent Elefteriou
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 2.  Osteoporosis in children and adolescents: etiology and management.

Authors:  Giampiero Igli Baroncelli; Silvano Bertelloni; Federica Sodini; Giuseppe Saggese
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 3.  Current treatments in familial dysautonomia.

Authors:  Jose-Alberto Palma; Lucy Norcliffe-Kaufmann; Cristina Fuente-Mora; Leila Percival; Carlos Mendoza-Santiesteban; Horacio Kaufmann
Journal:  Expert Opin Pharmacother       Date:  2014-10-17       Impact factor: 3.889

Review 4.  Semaphorin 3A: A new player in bone remodeling.

Authors:  Ren Xu
Journal:  Cell Adh Migr       Date:  2013-01-01       Impact factor: 3.405

5.  Calcitonin-gene-related peptide stimulates stromal cell osteogenic differentiation and inhibits RANKL induced NF-kappaB activation, osteoclastogenesis and bone resorption.

Authors:  Liping Wang; Xiaoyou Shi; Rong Zhao; Bernard P Halloran; David J Clark; Christopher R Jacobs; Wade S Kingery
Journal:  Bone       Date:  2009-12-02       Impact factor: 4.398

6.  Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro.

Authors:  Liping Wang; Rong Zhao; Xiaoyou Shi; Tzuping Wei; Bernard P Halloran; David J Clark; Christopher R Jacobs; Wade S Kingery
Journal:  Bone       Date:  2009-04-18       Impact factor: 4.398

Review 7.  No pain, no gain? The effects of pain-promoting neuropeptides and neurotrophins on fracture healing.

Authors:  Seungyup Sun; Nicklaus H Diggins; Zachary J Gunderson; Jill C Fehrenbacher; Fletcher A White; Melissa A Kacena
Journal:  Bone       Date:  2019-11-09       Impact factor: 4.398

8.  Sema3A regulates bone-mass accrual through sensory innervations.

Authors:  Toru Fukuda; Shu Takeda; Ren Xu; Hiroki Ochi; Satoko Sunamura; Tsuyoshi Sato; Shinsuke Shibata; Yutaka Yoshida; Zirong Gu; Ayako Kimura; Chengshan Ma; Cheng Xu; Waka Bando; Koji Fujita; Kenichi Shinomiya; Takashi Hirai; Yoshinori Asou; Mitsuhiro Enomoto; Hideyuki Okano; Atsushi Okawa; Hiroshi Itoh
Journal:  Nature       Date:  2013-05-05       Impact factor: 49.962

9.  Mice lacking substance P have normal bone modeling but diminished bone formation, increased resorption, and accelerated osteopenia with aging.

Authors:  Liping Wang; Saiyun Hou; Ilya Sabsovich; Tian-Zhi Guo; Tzuping Wei; Wade S Kingery
Journal:  Bone       Date:  2020-12-15       Impact factor: 4.398

10.  Bone biomechanical properties and tissue-scale bone quality in a genetic mouse model of familial dysautonomia.

Authors:  G Vahidi; H Flook; V Sherk; M Mergy; F Lefcort; C M Heveran
Journal:  Osteoporos Int       Date:  2021-05-25       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.